Quarterly ResultMay 6, 2026, 04:18 PM
Biote Q1 Revenue $44.9M, Net Income $2.7M; EPS $0.06
AI Summary
Biote Corp. reported first quarter 2026 financial results, with revenue decreasing 8.3% to $44.9 million and net income falling to $2.7 million from $15.8 million in Q1 2025. Diluted EPS was $0.06, down from $0.37. The results were impacted by supply constraints from a voluntary recall of hormone pellet products. The company expects continued headwinds in Q2 but anticipates a return to procedure revenue growth in the second half of 2026, maintaining its full-year guidance.
Key Highlights
- Revenue decreased 8.3% to $44.9 million in Q1 2026 from $49.0 million in Q1 2025.
- Net income was $2.7 million, down from $15.8 million in the prior year quarter.
- Diluted earnings per share attributable to stockholders was $0.06, compared to $0.37 in Q1 2025.
- Adjusted EBITDA declined 36.6% to $8.7 million, with a margin of 19.4%.
- Procedure revenue decreased 13.2% to $31.3 million due to a voluntary product recall.
- Dietary supplements revenue grew 19.1% to $11.0 million.
- Company expects a return to procedure revenue growth in the second half of 2026.
- Reaffirmed 2026 guidance: Revenue above $190 million and Adjusted EBITDA above $38 million.